Niloufar Pourfarrokh

Niloufar Pourfarrokh

Auto-generated profile, based on publicly available information

Niloufar Pourfarrokh

Departments of Pathology, Baylor Scott & White Health, 2401 S. 31 St., Temple, TX 76508, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2022 in Journal of Investigative Medicine High Impact Case Reports
Verified
Journal Article
Open access
NPNiloufar Pourfarrokh
Niloufar Pourfarrokh
YWYilun Wang
Yilun Wang
CCConstance Cleaves
Constance Cleaves
RZRiyam Zreik
Riyam Zreik
BLBing Leng
Bing Leng
Solitary fibrous tumor (SFT) is a mesenchymal tumor accounting for less than 2% of soft tissue tumors and has variable clinical behavior. It can arise in many anatomical locations of the body and in rare occasions in the oral cavity mostly in buccal mucosa and tongue. To date, a handful of such cases have been reported in the hard palate. We present a case of SFT in the hard palate of a 32-year-old man and describe the tissue morphology, immunohistochemistry workup, and follow-up together with literature review.

24 July 2023 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
GJGarrett L. Jensen
Garrett L. Jensen
NPNiloufar Pourfarrokh
Niloufar Pourfarrokh
MVMarcus Volz
Marcus Volz
LMLinden L. Morales
Linden L. Morales
KWKimberly Walker
Kimberly Walker
SJSameer Jhavar
Sameer Jhavar
With the growing interest in total neoadjuvant treatment for locally advanced rectal adenocarcinoma (LARC) there is an urgent unmet need to identify predictive markers of response to long-course neoadjuvant concurrent chemoradiotherapy (LCRT). O6-Methylguanine (O6-MG)-DNA-methyltransferase (MGMT) gene methylation has been associated in some malignancies with response to concurrent chemoradiotherapy. We attempted to find if pathologic response to LCRT was associated with MGMT promoter hypermethylation (MGMTh). Patients were identified with LARC, available pre-treatment biopsy specimens, and at least 1 year of follow-up who received LCRT followed by surgical resection within 6 months. Biopsies were tested for MGMTh using a Qiagen pyrosequencing kit (Catalog number 970061). The primary outcome of LCRT responsiveness was based on tumor regression grade (TRG), with grades of 0–1 considered to have excellent response and grades of 2–3 considered to be non-responders. Secondary outcomes included overall survival (OS) and recurrence free survival (RFS). Of 96 patients who met inclusion criteria, 76 had samples which produced reliable assay results. MGMTh corresponded with higher grade and age of the biopsy specimen. The percentage of responders to LCRT was higher amongst the MGMTh patients than the MGMTn patients (60.0% vs 27.5%, p value = 0.0061). MGMTh was not significantly associated with improved OS (2-year OS of 96.0% vs 98.0%, p = 0.8102) but there was a trend for improved RFS (2-year RFS of 87.6% vs 74.2%, p = 0.0903). Significantly greater tumor regression following LCRT was seen in MGMTh LARC. Methylation status may help identify good candidates for close observation without surgery following LCRT.

4 August 2022 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
NPNiloufar Pourfarrokh
Niloufar Pourfarrokh
CCChrystalle Katte Carreon
Chrystalle Katte Carreon
RZRiyam Zreik
Riyam Zreik
JAJaya Ruth Asirvatham
Jaya Ruth Asirvatham
Heterotopic hepatic tissue in placenta or umbilical cord is rare. The exact mechanism by which this heterotopia occurs has not been fully understood but is thought to be related to yolk sac primordia. To date, a handful of such cases have been reported. We present a case of heterotopic liver tissue within a chorionic stem villus of a 37 week-growth restricted neonate and describe the tissue morphology and its immunohistochemistry workup.